What one share of Theriva Biologics holds
We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L.
Theriva Biologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.42 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.41 |
| Cash and investments | $0.25 |
| Debt | $0.04 |
| Book value | $0.27 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$2,529 | $52.80 | −$2,642 | — | — |
| 2017 | — | −$1,557 | $14.92 | −$1,436 | — | — |
| 2018 | — | −$1,014 | $0.28 | −$693.39 | — | — |
| 2019 | — | −$244.49 | $0.00 | −$210.99 | — | — |
| 2020 | — | −$165.12 | $0.12 | −$160.13 | — | — |
| 2021 | — | −$47.57 | $0.03 | −$26.47 | — | — |
| 2022 | — | −$32.66 | $0.19 | −$31.31 | — | — |
| 2023 | — | −$28.48 | $0.31 | −$29.80 | — | — |
| 2024 | — | −$19.03 | $0.00 | −$12.56 | — | — |
| 2025 | — | −$2.08 | $0.00 | −$1.38 | — | $0.43 |
Common questions about Theriva Biologics
How much does one share of Theriva Biologics earn?
Over the last 12 months, Theriva Biologics lost $0.42 for each share.
Does Theriva Biologics pay a dividend?
Theriva Biologics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Theriva Biologics’s book value per share?
Theriva Biologics’s book value is $0.27 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Theriva Biologics have?
Each share of Theriva Biologics has $0.25 of cash and investments and $0.04 of debt, as of June 30, 2026.
What is Theriva Biologics’s free cash flow per share?
−$0.41 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Theriva Biologics bought back shares?
Theriva Biologics’s share count rose about 112564% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.